Published in Ann Neurol on February 01, 1994
Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain (2005) 3.61
Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest (2005) 2.25
Cell therapy in Parkinson's disease. NeuroRx (2004) 1.93
Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. J Neurosci (1996) 1.59
The promise and perils of stem cell therapeutics. Cell Stem Cell (2012) 1.50
Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. PLoS One (2009) 1.38
Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS One (2011) 1.35
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Cellular transplantation strategies for spinal cord injury and translational neurobiology. NeuroRx (2004) 1.23
Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J Neurol (2009) 1.05
Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord (2010) 1.02
Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS One (2007) 0.99
Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis (2007) 0.98
Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol (2015) 0.97
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain (2008) 0.94
Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A (2016) 0.94
Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease? Proc Natl Acad Sci U S A (2002) 0.92
PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice. Brain (2012) 0.91
Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinsons Dis (2012) 0.89
Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol (2014) 0.86
The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules (2015) 0.84
Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull (2005) 0.83
Evidence from clinical trials: can we do better? NeuroRx (2004) 0.83
Transplantation of fetal cells and tissue: an overview. CMAJ (1994) 0.83
Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges. Neurotherapeutics (2011) 0.81
Development of stem cell-based therapy for Parkinson's disease. Transl Neurodegener (2015) 0.80
Pluripotent stem cells for Parkinson's disease: progress and challenges. Stem Cell Res Ther (2013) 0.80
Fetal grafts for Parkinson's disease: Decades in the making. Proc Natl Acad Sci U S A (2016) 0.80
Stem cell transplantation in neurological diseases: improving effectiveness in animal models. Front Cell Dev Biol (2014) 0.79
Cell Biology and Pathophysiology of α-Synuclein. Cold Spring Harb Perspect Med (2017) 0.79
Fetal stem cell transplantation: Past, present, and future. World J Stem Cells (2014) 0.78
Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proc Natl Acad Sci U S A (2013) 0.78
Positron emission tomography imaging of transplant function. NeuroRx (2004) 0.78
Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease. Parkinsons Dis (2012) 0.78
Differentiation of rhesus adipose stem cells into dopaminergic neurons. Neural Regen Res (2012) 0.77
The design of clinical trials for cell transplantation into the central nervous system. NeuroRx (2004) 0.77
Critical aspects of clinical trial design for novel cell and gene therapies. Parkinsons Dis (2011) 0.76
Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease. Stem Cell Rev (2016) 0.76
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. Basal Ganglia (2012) 0.76
Clinical application of neuronal grafts in Parkinson's disease. J Neurol (1994) 0.76
Mapping human brain activity in vivo. West J Med (1994) 0.76
Cellular repair strategies in Parkinson's disease. Ther Adv Neurol Disord (2009) 0.76
Proceedings: cell therapies for Parkinson's disease from discovery to clinic. Stem Cells Transl Med (2014) 0.75
Stem Cell-Mediated Regeneration of the Adult Brain. Transfus Med Hemother (2016) 0.75
Effects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease. Stem Cells Transl Med (2016) 0.75
Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Mol Ther Methods Clin Dev (2016) 0.75
Brain repair: an overview. J Neurol (1994) 0.75
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Regulation of the bacterial cell wall: analysis of a mutant of Bacillus subtilis defective in biosynthesis of teichoic acid. J Bacteriol (1972) 5.55
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Servo action in the human thumb. J Physiol (1976) 4.93
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin (2001) 4.41
Servo action in human voluntary movement. Nature (1972) 4.33
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Writers' cramp-a focal dystonia. Brain (1982) 3.43
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Corticobasal degeneration. Brain (1989) 3.20
Asia Pacific consensus recommendations for colorectal cancer screening. Gut (2008) 3.19
A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest (2001) 3.18
Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol (1996) 3.16
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. Neurology (2011) 3.15
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci (1999) 3.06
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord (1999) 2.98
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits. Exp Brain Res (1998) 2.90
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Identifying global anatomical differences: deformation-based morphometry. Hum Brain Mapp (1998) 2.74
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Distribution of cortical neural networks involved in word comprehension and word retrieval. Brain (1991) 2.66
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
'Theory of mind' in the brain. Evidence from a PET scan study of Asperger syndrome. Neuroreport (1996) 2.60
History of exposure to dopaminergic medication does not affect motor cortex plasticity and excitability in Parkinson's disease. Clin Neurophysiol (2012) 2.60
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
The effect of percutaneous motor cortex stimulation on H reflexes in muscles of the arm and leg in intact man. J Physiol (1986) 2.47
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
The physiological basis of transcranial motor cortex stimulation in conscious humans. Clin Neurophysiol (2004) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol (2000) 2.41
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Activation of the human diaphragm from the motor cortex. J Physiol (1987) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature (1987) 2.33
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage (1997) 2.29
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ (1993) 2.24
Pathophysiology of bradykinesia in Parkinson's disease. Brain (2001) 2.24
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Pathogenesis of the urethral syndrome in women and its diagnosis in general practice. Lancet (1972) 2.21